Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors
Gemcitabine is widely used for pancreatic, lung, and bladder cancer. However, drug resistance against gemcitabine is a large obstacle to effective chemotherapy. Nucleoside transporters, nucleoside and nucleotide metabolic enzymes, and efflux transporters have been reported to be involved in gemcitab...
Main Authors: | Kentaro Minami, Yoshinari Shinsato, Masatatsu Yamamoto, Homare Takahashi, Shaoxuan Zhang, Yukihiko Nishizawa, Sho Tabata, Ryuji Ikeda, Kohich Kawahara, Kazutake Tsujikawa, Kazuo Chijiiwa, Katsushi Yamada, Shin-ichi Akiyama, Sandra Pérez-Torras, Marcal Pastor-Anglada, Tatsuhiko Furukawa, Takeda Yasuo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-03-01
|
Series: | Journal of Pharmacological Sciences |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1347861315000092 |
Similar Items
-
mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer
by: Ling Tian, et al.
Published: (2021-07-01) -
Advances of Drug Resistance Marker of Gemcitabine for Non-small Cell Lung Cancer
by: Baorui LIU, et al.
Published: (2011-05-01) -
Repair, consequence, and profile of ribonucleotides in DNA
by: Koh, Kyung Duk
Published: (2015) -
Vaccinia virus DNA polymerase and ribonucleotide reductase: their role in replication, recombination and drug resistance
by: Gammon, Donald Brad
Published: (2009) -
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
by: Kunos Charles, et al.
Published: (2012-04-01)